Ryon Graf, PhD
@RyonGraf
Followers
582
Following
4K
Media
51
Statuses
2K
Biomedical scientist & ocean lover. Into diagnostics, biostatistics, & outcomes-based evidence. Employer: @FoundationATCG Opinions: my own. RT≠endorsement.
San Diego, CA
Joined July 2013
RT @PTarantinoMD: The results of SONIA are out on @Nature. 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An….
0
84
0
RT @wandering_gu: 🚨 New pub: real-world PARP-I response in mCRPC according to DDR alteration status. Huge credit to 💫 @UMichUrology chief….
0
5
0
RT @BrunaPellini: 🚨Happy to share our exciting #ctDNA monitoring research in metastatic NSCLC hot off the press @CCR_AACR 👇.
0
41
0
RT @FoundationATCG: In a letter to @CellPressNews' Cancer Cell, our scientists share new research demonstrating a consistent association be….
0
3
0
RT @wandering_gu: OS data from PROPEL (Olaparib + Abi) in 1st line mCRPC. 7 mo median OS benefit (p=0.054). But really driven by HRRm subgr….
0
9
0
RT @AzadOncology: @Ecastromarcos @ASCO #GU23 discussing Talapro-2 & Triton-3 abstracts. Ongoing Qs/challenges:. 1. Where will PARPi best fi….
0
5
0
RT @wandering_gu: Beautiful summary of mCRPC treatment options with recommended algorithms by @Silke_Gillessen #GU23
0
6
0
RT @DrRanaMcKay: Amazing data presented from Talapro-2 by @neerajaiims on the heals of Propel and Magnitude providing future support of PAR….
0
7
0
RT @ERPlimackMD: Surprised to hear such emphatic support of PFS wout OS benefit for PARPi in #prostatecancer when 1 in 4 on PARPi require o….
0
19
0
RT @tompowles1: Talapro-2 ⬆️ rPFS for talazoparib/enza in unselected CRPC with more benefit in HRR as with olaparib/abi. Titron-3 showed ru….
0
46
0
RT @shilpaonc: @Ecastromarcos delivers an elegant &. thoughtful discussion of TALAPRO2 @neerajaiims and TRITON3 @AlanBryce9 . We need to u….
0
4
0
RT @wandering_gu: Important take home slide from @Ecastromarcos on PARPi role in mCRPC. BRCA>HRRm>all comers>non-HRRm. #GU23
https://t.co….
0
9
0
RT @JCOPO_ASCO: 👀 Check out what’s popular this week in #JCOPO:. Tumor Fraction Correlates With Detection of Actionable Variants Across > 2….
0
5
0
RT @NatRevClinOncol: Study shows that plasma cfDNA tumour fraction is a pragmatic, independent prognostic biomarker across across pts with….
0
16
0
RT @Annals_Oncology: This article in Annals of Oncology reports on the prognostic value of ctDNA fraction across different tumor types usin….
0
12
0
RT @sidlipsey: Loving John Smoltz’s on-air hat tip to the late Tony Gwynn. I knew Gwynn did well against that Braves Hall of Fame ‘90s rota….
0
2
0
RT @StoverLab: Great collab evaluating hypothesis that ctDNA tumor fraction may be prognostic across cancers. Full 🧵to follow!. What a tea….
0
8
0
RT @shilpaonc: @GUONCGarciaJA gives a shoutout to @neerajaiims @umangtalking on their work on #SPOP mutations as a predictive biomarker in….
0
9
0
RT @MyriamChalabi: About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patien….
0
251
0
RT @KlempnerSam: Ever since #ESMO22 @myESMO I have been seeing #ChalabiPlot all over. Found this one and the likely EFS curve in the woodp….
0
4
0